On May 26, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that six clinical abstracts demonstrating the broad use of its NeXT Personal test will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 to June 2 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal’s single-digit parts-per-million (ppm) sensitivity in early-stage non-small cell lung cancer (NSCLC). By detecting circulating tumor DNA (ctDNA) at these ultra-low thresholds, NeXT Personal continues to set new benchmarks for MRD test performance.

"At ASCO (Free ASCO Whitepaper), our collaborators will present data that underscores the critical importance of ultrasensitive MRD testing across six distinct solid tumor types, including exceptional new data in colorectal and lung cancer," said Richard Chen, MD, President and Chief Medical Officer of Personalis. "This data builds upon foundational evidence from our landmark publications in breast cancer, lung cancer, and immunotherapy monitoring, confirming that the ultrasensitive detection provided by NeXT Personal enables early identification of recurrence and precise assessments of therapy response."

Key clinical highlights at ASCO (Free ASCO Whitepaper) include:

Ultrasensitive Colorectal Cancer Data (VICTORI Study): Updated results from the prospective VICTORI surveillance cohort, led by the University of British Columbia, highlight NeXT Personal’s strong performance in detecting ctDNA among Stage I-III colorectal cancer patients. The test achieved 100% longitudinal sensitivity for recurrence—including difficult-to-detect metastatic sites—and >80% landmark sensitivity as early as four weeks post-surgery.
Clinical Importance of Ultrasensitive ctDNA Detection at Single-Digit Levels (TRACERx Podium Presentation): Utilizing samples from the TRACERx lung cancer cohort, investigators demonstrate that NeXT Personal ctDNA detections at the very lowest levels <10ppm identify patients at high risk for relapse.
Expanded Clinical Evidence for NeXT Personal Across Solid Tumor Types: New clinical data will be presented across six cancer types, including colorectal, lung, melanoma, ovarian, endometrial, and renal cell cancers.
Presentation Schedule

Oral Podium Presentation

Title: Clinical validity of ultrasensitive single-digit parts per million ctDNA detection in non–small cell lung cancer (TRACERx)
Presenter: Jonathan Wan, MD, PhD, University College London
Abstract: #8017 | Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Time: May 31, 2026, 4:30 PM–6:00 PM CDT
Poster Presentations

Colorectal Cancer (VICTORI Study): Minimal residual disease (MRD) detection using an ultra-sensitive assay in a prospective colorectal cancer cohort: Updates from the VICTORI study. (University of British Columbia). Abstract #396 | Session: Gastrointestinal Cancer | Time: May 30, 2026, 9:00 AM–12:00 PM CDT
Renal Cell Carcinoma: Ultrasensitive circulating tumor DNA detection and molecular clearance as a prognostic and predictive marker in advanced renal cell carcinoma. (Instituto de Investigación Sanitaria – IDIS). Abstract #30 | Session: Genitourinary Cancer | Time: May 31, 2026, 9:00 AM–12:00 PM CDT
Melanoma: Ultrasensitive ctDNA detection for relapse and response prediction in melanoma patients treated with immunotherapy. (University Medical Center Hamburg-Eppendorf – UKE). Abstract #288 | Session: Melanoma/Skin Cancers | Time: May 31, 2026, 9:00 AM–12:00 PM CDT
Endometrial Cancer: Ultra-sensitive circulating tumor DNA (ctDNA) detection as a predictor of survival outcomes in endometrial cancer patients undergoing frontline treatment. (MD Anderson Cancer Center). Abstract #277 | Session: Gynecologic Cancer | Time: June 1, 2026, 9:00 AM–12:00 PM CDT
Ovarian Cancer: Circulating tumor DNA enhances detection of high-risk minimal residual disease in ovarian cancer relative to second-look laparoscopy. (MD Anderson Cancer Center). Abstract #233 | Session: Gynecologic Cancer | Time: June 1, 2026, 9:00 AM–12:00 PM CDT

(Press release, Personalis, MAY 26, 2026, View Source [SID1234666077])

On May 26, 2026 NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, reported it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstracts demonstrate NeoGenomics’ expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center.

To support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.

NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company’s new tagline, ‘Answers are in our DNA.’

"A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring," said Tony Zook, CEO of NeoGenomics. "The breadth of our ASCO (Free ASCO Whitepaper) research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient."

Presentations and online abstracts at ASCO (Free ASCO Whitepaper) include:

Poster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing
Session: Quality Care/Health Services Research
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #337: From Infancy to Young Adulthood: Exploring the divergent genomic mechanisms that drive AML
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Monday, June 1, 9 AM to 12 PM CDT | Hall A
Poster #129a: Interception of Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study (NCT06643585)
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Poster #135a: The SURVIVE Study: Re-evaluating Follow-up in Early Breast Cancer
Session: Breast Cancer—Local/Regional/Adjuvant
Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
Online Abstract: Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants
Online Abstract: Real-world evidence for comprehensive genomic profiling in myeloid malignancies: changes in detection and clinical impact
Online Abstract: Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center
Online Abstract: Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression

(Press release, NeoGenomics Laboratories, MAY 26, 2026, View Source [SID1234666076])

On May 26, 2026 Incyte (Nasdaq:INCY) reproted that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

(Press release, Incyte, MAY 26, 2026, View Source [SID1234666075])

On May 26, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The event will take place May 29 – June 3, 2026 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s ASCO (Free ASCO Whitepaper) Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies."

Research highlights include:

Saturday, May 30, 2026
9:00am – 12:00pm CT

Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success
Poster Board: 536; Abstract Number: 1618

AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.
Poster Board: 193; Abstract Number: 4210

1:30 pm – 4:30 pm CT

ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy
Poster Board: 199; Abstract Number: 3062

First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
Poster Board: 509; Abstract Number: 6052

Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors
Poster Board: 219; Abstract Number: 3082

Sunday, May 31, 2026
9:00am – 12:00pm CT

Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing
Poster Board: 518; Abstract Number: 8044

Monday, June 1, 2026
9:00 am – 12:00 pm CT

Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Poster Board: 363; Abstract Number: 6570

1:30 pm – 4:30 pm CT

GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies
Poster Board: 130b; Abstract Number: TPS649

Explore the full scope of Tempus-authored research and discover how the company is advancing precision medicine at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting here.

(Press release, Tempus, MAY 26, 2026, View Source [SID1234666073])

On May 26, 2026 Hologic, Inc. and its subsidiary, Biotheranostics, Inc., reported new data demonstrating how the Breast Cancer Index (BCI) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive (HR+) breast cancer. According to the latest analysis, physician recommendations for extended endocrine therapy increased by more than 30% among patients identified by the BCI Test as likely to benefit, while recommendations decreased by nearly 40% for those identified as unlikely to benefit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BCI Test is the established test for extended endocrine therapy decision-making, with exclusive guideline recognition from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) for this purpose. Both classify the BCI Test as the only genomic assay shown to predict who is likely to benefit from extended endocrine therapy beyond five years.2,3

More information on these findings will be presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting on June 1. The data come from a new analysis of the ongoing BCI Registry Study, which evaluates how physicians incorporate prognostic and predictive BCI Test results into real-world treatment decisions.

"Understanding who is likely to benefit from extended endocrine therapy is critical to personalizing care," said Sami Diab, M.D., Medical Director, Oncology at Hologic. "Findings from the BCI Registry Study continue to highlight the real-world impact of the Breast Cancer Index Test in helping physicians make more informed treatment recommendations for their patients."

Detailed findings from the analysis include:

Overall:
The percentage of patients recommended for extended endocrine therapy decreased from 54.6% before BCI testing to 41.2% after BCI testing.
The percentage of patients not recommended for extended endocrine therapy increased from 44.9% before testing to 58% after testing.
Among patients identified by the BCI Test as likely to benefit from extended endocrine therapy (BCI H/I-High):
Physician recommendations for extended endocrine therapy increased from 60.4% before testing to 90.6% after testing.
Among patients identified as unlikely to benefit (BCI H/I-Low):
Recommendations decreased from 51.1% to 11.8%.
"Decisions about extended endocrine therapy are complex, requiring physicians to balance recurrence risk, potential side effects, and clinical and pathologic factors," said Tara B. Sanft, M.D., of Hartford Healthcare and lead author of the study. "Findings from the BCI Registry Study suggest that relying on those factors alone may not provide enough information for physicians and patients to make decisions with confidence. Genomic testing with the Breast Cancer Index Test provides additional insight into tumor biology, helping physicians refine extended endocrine therapy recommendations and better identify which patients are most likely to benefit."

Learn more on June 1, 2026, 1:30-4:30 p.m. CDT at ASCO (Free ASCO Whitepaper) 2026: Impact of the Breast Cancer Index on Extended Endocrine Therapy Recommendations in Patients from the BCI Registry Study1 (Abstract #527/Poster Board #12 — Breast Cancer — Local/Regional/Adjuvant)

About the Breast Cancer Index Test

The Breast Cancer Index Test is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early-stage, HR+ breast cancer. This breakthrough test helps oncology care teams and patients navigate the difficult trade-offs between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment.

The Breast Cancer Index Test has guideline designation from the American Joint Committee on Cancer for cancer staging based on molecular profile. The ASCO (Free ASCO Whitepaper) Clinical Practice Guideline and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) acknowledge the Breast Cancer Index Test as a biomarker to help inform extended endocrine treatment decisions.2,3

The Breast Cancer Index Test is intended for routine clinical use, and physician treatment decisions based on results are the responsibility of the physician. It is a sole-source laboratory-developed test (LDT) performed by Biotheranostics, Inc., a CLIA-certified and CAP-accredited diagnostic laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit www.breastcancerindex.com.

(Press release, Hologic, MAY 26, 2026, View Source [SID1234666072])